跳至主要内容

Great news! Medicilon Analytical Testing Center has passed the CNAS on-site assessment!

Recently, the Analytical Testing Center of Shanghai Medicilon Inc. (Medicilon) successfully passed the on-site assessment by the China National Accreditation Service for Conformity Assessment (CNAS).  This marks that Medicilon's Analytical Testing Center has achieved international recognition standards for its testing results and service quality, laying a solid foundation for the company's continuous deepening in the biopharmaceutical R&D field and expansion into international markets in the future.



During this assessment, the CNAS expert team conducted a comprehensive and in-depth inspection of Medicilon's laboratory, covering several key aspects such as the quality manual, procedural documents, operational guidelines, on-site instruments and equipment, and experimental operations.  Following a series of rigorous and professional review procedures, the expert team unanimously concluded that Medicilon's laboratory met the highest requirements of international standards, including ISO/IEC 17025:2017 "General Requirements for the Competence of Testing and Calibration Laboratories," in terms of its management system, technical capabilities, and operational standards.

The total area of Medicilon's Analytical Testing Center Laboratory exceeds 2,800 square meters. Its GMP system has successfully passed multiple on-site inspections by the NMPA.  Currently, Medicilon's Analytical Testing Center has established platforms for various services, including genotoxicity research, physicochemical characterization research, microbiological research, impurity preparation and structure identification, trace impurity and residual solvent analysis, trace elemental impurity analysis, safety assessment tests, analytical method development, and quality control. These platforms can provide integrated drug analysis solutions and technical services to clients, encompassing routine physicochemical testing, specialized testing, chromatographic testing, and more. This supports new drug development, pharmaceutical CMC applications, and production release, aiding in the launch and internationalization of new drugs.

Meeting international mutual recognition standards, the test reports have been certified by international authorities

As an important member of the international laboratory mutual recognition system, CNAS accreditation signifies that Medicilon's Analytical Testing Center has established a quality management system that meets international standards and possesses the technical capabilities to perform calibration and testing according to the highest international standards.  This accreditation not only serves as an authoritative recognition of Medicilon's technical strength and service quality but also bestows international authority and credibility on its test reports.

Promote the deepening of international collaboration and continuously advances the process of internationalization

Under the wave of globalization, international collaboration in the field of biopharmaceutical research and development is becoming increasingly frequent.  As a CNAS-accredited laboratory, Medicilon aims to seamlessly integrate into the international R&D network, sharing resources, exchanging experiences, and fostering collaborative innovation with global peers.  This not only helps Medicilon showcase its technological strength and innovative achievements on the global stage but also injects new momentum into the internationalization of China's biopharmaceutical industry.

Actively benchmarking against international frontiers, upgrading and empowering the R&D "Arsenal"

It's worth noting that Medicilon's CNAS on-site accreditation was not achieved overnight but stems from the company's years of relentless pursuit of technological innovation, rigorous quality management, and deep commitment to internationalization strategies.  In 2023, Medicilon achieved several significant milestones, including obtaining GLP certification from the National Medical Products Administration for newly added experimental facilities and filing for ABSL-2 laboratory accreditation.  At the same time, Medicilon actively absorbs international cutting-edge technology and advanced equipment, continuously upgrading and empowering its R&D "Arsenal."

Looking ahead, Medicilon will continue to uphold its service philosophy of 'innovation-driven, quality-focused’. With the CNAS on-site accreditation as a catalyst, Medicilon will further intensify investments and explorations in the biopharmaceutical R&D field, continuously enhancing the laboratory's technological capabilities and management standards.  At the same time, Medicilon will actively participate in international exchanges and collaboration activities, advancing the internationalization of China's biopharmaceutical R&D service industry. Medicilon aims to contribute more Chinese wisdom and strength to the prosperity and progress of the global biopharmaceutical industry!

About CNAS

China National Accreditation Service for Conformity Assessment (CNAS) is the authoritative organization designated by the State Administration for Market Regulation of China, in accordance with the Regulations on Certification and Accreditation of the People's Republic of China and the Measures for the Supervision and Administration of Accreditation Institutions. CNAS is responsible for accrediting assessment activities of certification authorities, laboratories, inspection authorities, appraisal and verification authorities, and other conformity assessment authorities. It operates the national accreditation system for conformity assessment authorities in China.

CNAS is a full member of the International Accreditation Forum (IAF), the International Laboratory Accreditation Cooperation (ILAC), and the Asia-Pacific Accreditation Cooperation (APAC).  Obtaining CNAS accreditation provides opportunities to participate in bilateral and multilateral collaboration and exchanges among internationally recognized conformity assessment authorities.  Within its scope of accreditation, the testing reports issued by CNAS-accredited laboratories carry international credibility and authority.

标签：
地点: 美国

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文